Search Result

Results for "

estrogen receptor modulator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Estrogen Receptor/ERR (63) Apoptosis (11) Aryl Hydrocarbon Receptor (1) Autophagy (7) Bcl-2 Family (1) Biochemical Assay Reagents (1) Caspase (1) COX (1) Dengue virus (1) Endogenous Metabolite (4) Flavivirus (1) Glucocorticoid Receptor (1) HSP (5) Isotope-Labeled Compounds (8) LXR (1) VEGFR (1)
By Research Areas:	Cancer (46) Cardiovascular Disease (3) Endocrinology (20) Infection (6) Inflammation/Immunology (2) Metabolic Disease (6) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Estrogen Receptor/ERR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-110201

Estrogen receptor modulator 1	Estrogen Receptor/ERR	Cancer
Estrogen receptor modulator 1 (compound 18) is an orally active and selective **estrogen receptor** modulator (SERM), with a pIC₅₀ of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors .

HY-153478

Estrogen receptor modulator 7	Estrogen Receptor/ERR	Cancer
Estrogen receptor modulator 7 is a potent **estrogen receptor** modulator. Estrogen receptor modulator 7 can be used in research of cancer .

HY-155406

Estrogen receptor modulator 10	Estrogen Receptor/ERR Caspase Bcl-2 Family	Cancer
Estrogen receptor modulator 10 (compound G-5b) is an **Estrogen receptor (ER) antagonist (IC₅₀=6.7 nM) and degrader (DC₅₀*=0.4 nM). Estrogen* receptor modulator 10 can induce apoptosis. Estrogen receptor modulator 10 can block cells at the G1/G0 phase. Estrogen receptor modulator 10 can be used in cancer studies .

HY-138690

Estrogen receptor modulator 6	Estrogen Receptor/ERR	Endocrinology
Estrogen receptor modulator 6 (compound 3a) is a selective estrogen receptor (ER) β agonist (K_i=0.44 nM). Estrogen receptor modulator 6 displays 19-fold selectivity for ERβ over ERα(K_i=8.4 nM) .

HY-153700

Estrogen receptor modulator 8	Estrogen Receptor/ERR	Endocrinology
Estrogen receptor modulator 8 (compound 4) is an orally active inhibitor of Estrogen Receptor/ERR α (IC₅₀=0.437 nM, MCF-7 cells). Estrogen receptor modulator 8 inhibits MCF-7 cells proliferation with an IC₅₀ value of 0.1 nM .

HY-122359B

Levormeloxifene fumarate L-Centchroman fumarate	Estrogen Receptor/ERR	Others
Levormeloxifene (fumarate) is a stable salt form of Levormeloxifene. Levormeloxifene (fumarate) is an **estrogen receptor** modulator that plays an important role in prevention of postmenopausal bone loss .

HY-A0036

Bazedoxifene acetate 5+ Cited Publications TSE-424 acetate	Estrogen Receptor/ERR	Cancer
Bazedoxifene acetate (TSE-424 acetate) is an oral, nonsteroidal *selective estrogen* receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene acetate can be used for the research of osteoporosis. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130** protein-protein interactions and can be used for the research of pancreatic cancer .

HY-A0031

Bazedoxifene 5+ Cited Publications TSE-424	Estrogen Receptor/ERR	Cancer
Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal *selective estrogen* receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130** protein-protein interactions and can be used for the research of pancreatic cancer .

HY-A0031A

Bazedoxifene hydrochloride TSE-424 hydrochloride	Estrogen Receptor/ERR	Cancer
Bazedoxifene hydrochloride (TSE-424 hydrochloride) is an oral active, BBB-penetrant nonsteroidal *selective estrogen* receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene hydrochloride can be used for the research of osteoporosis. Bazedoxifene hydrochloride acts as an inhibitor of IL-6/GP130** protein-protein interactions. Bazedoxifene hydrochloride can be used for the research of pancreatic cancer .

HY-13724

Pipendoxifene

ERA-923
Estrogen Receptor/ERR Cancer

Pipendoxifene is a selective estrogen receptor modulator (SERM).

Pipendoxifene ERA-923	Estrogen Receptor/ERR	Cancer
Pipendoxifene is a selective **estrogen receptor** modulator (SERM).

HY-B0723

Ospemifene 2 Publications Verification FC-1271a	Estrogen Receptor/ERR	Cancer
Ospemifene is a non-estrogen selective **estrogen receptor** modulator (SERM), with K_is of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene can be used for the research of vaginal atrophy and breast cancer .

HY-N2371

27-Hydroxycholesterol 2 Publications Verification 27-OHC	Estrogen Receptor/ERR LXR Endogenous Metabolite	Cancer
27-Hydroxycholesterol (27-OHC) is a selective **estrogen receptor** modulator and an agonist of the liver X receptor.

HY-13556A

Arzoxifene hydrochloride LY353381 hydrochloride; SERM III hydrochloride	Estrogen Receptor/ERR	Cancer
Arzoxifene (LY353381) hydrocloride is a selective **estrogen receptor** modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.

HY-U00178

Idoxifene

CB7432
Estrogen Receptor/ERR Cancer

Idoxifene (CB7432) is a novel tissue-specific selective estrogen receptor modulator (SERM).

Idoxifene CB7432	Estrogen Receptor/ERR	Cancer
Idoxifene (CB7432) is a novel tissue-specific selective **estrogen receptor** modulator (SERM).

HY-13724B

Pipendoxifene hydrochloride	Estrogen Receptor/ERR	Cancer
Pipendoxifene hydrochloride is a selective **estrogen receptor** modulator (SERM) that can be used for the research of breast cancer .

HY-13738A

Raloxifene hydrochloride 5+ Cited Publications Keoxifene hydrochloride; LY156758; LY139481 hydrochloride	Estrogen Receptor/ERR Autophagy	Endocrinology Cancer
Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active **estrogen receptor** modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .

HY-13738

Raloxifene 5+ Cited Publications Keoxifene; LY156758 free base; LY139481	Estrogen Receptor/ERR	Cancer
Raloxifene (Keoxifene) is a benzothiophene-derived selective **estrogen receptor** modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-15731

Estetrol	Estrogen Receptor/ERR Endogenous Metabolite	Cardiovascular Disease
Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear **estrogen receptor** modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast .

HY-135585

LY88074	Others	Endocrinology
LY88074 (Compound 88074) is a Raloxifene analog lacking the basic side chain. Raloxifene is a selective estrogen receptor modulator, and reduces fracture risk at least in part by improving the mechanical properties of bone in a cell- and estrogen receptor-independent manner .

HY-135671

AhR modulator-1	Aryl Hydrocarbon Receptor VEGFR Estrogen Receptor/ERR	Endocrinology Cancer
AhR modulator-1 (compound 6-MCDF) is a selective and orally active *aryl hydrocarbon receptor* (AhR)** modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus .

HY-16950B

(E)-4-Hydroxytamoxifen (E)-Afimoxifene	Estrogen Receptor/ERR	Cancer
(E)-4-Hydroxytamoxifen ((E)-Afimoxifene), the less active isomer of (Z)-4-hydroxytamoxifen, is an **estrogen receptor** modulator.

HY-13738S

Raloxifene-d4	Isotope-Labeled Compounds Estrogen Receptor/ERR	Cancer
Raloxifene-d₄ is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].

HY-13738S2

Raloxifene-d4 hydrochloride	Isotope-Labeled Compounds Estrogen Receptor/ERR	Cancer
Raloxifene-d₄ (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].

HY-13738S3

Raloxifene-d10	Isotope-Labeled Compounds Estrogen Receptor/ERR	Cancer
Raloxifene-d₁₀ is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].

HY-13738AR

Raloxifene hydrochloride (Standard) Keoxifene (hydrochloride)(Standard); LY156758(Standard); LY139481 hydrochloride (Standard)	Estrogen Receptor/ERR Autophagy	Endocrinology Cancer
Raloxifene (hydrochloride) (Standard) is the analytical standard of Raloxifene (hydrochloride). This product is intended for research and analytical applications. Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation?selective and orally active **estrogen receptor** modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .

HY-15731S

Estetrol-d4	Isotope-Labeled Compounds Estrogen Receptor/ERR Endogenous Metabolite	Cardiovascular Disease
Estetrol-d₄ is the deuterium labeled Estetrol. Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast[1][2].

HY-B2158

Chlorotrianisene
Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active **estrogen receptor** modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood .

HY-116896

LY117018	Estrogen Receptor/ERR	Cancer
LY117018, a Raloxifene analog, is a selective **estrogen receptor** modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines .

HY-13738S4

Raloxifene-d10-1 Keoxifene-d₁₀; LY156758(free base)-d₁₀; LY139481-d₁₀	Estrogen Receptor/ERR	Cancer
Raloxifene-d₁₀-1 is the deuterium labeled Raloxifene[1]. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[2].

HY-N1556

Psidial A
Psidial A is an epimer of sesquiterpenoid-diphenylmethane meroterpenoid. Psidial A may act as a selective estrogen receptors modulator. Psidial A also has potential for anticancer research .

HY-B0723S

Ospemifene D4 FC-1271a d₄	Estrogen Receptor/ERR	Cancer
Ospemifene-d₄ is a deuterium labeled Ospemifene. Ospemifene is a selective and orally active estrogen receptor modulator for the prevention of osteoporosis with IC50 values of 827 nM and 1633 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene has bone-sparing, antitumor, and cholesterol-lowering effects[1][2].

HY-143226

DK1	Estrogen Receptor/ERR	Metabolic Disease
DK1 is a potent modulator of **estrogen related receptor*. DK1 has an ability in reducing blood glucose, and impacts the activity of ERRα receptor*. DK1 has the potential for the research of diabetes .

HY-13556

Arzoxifene LY353381; SERM III	Estrogen Receptor/ERR	Metabolic Disease
Arzoxifene (LY353381) is an orally active selective **estrogen receptor** modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile .

HY-116896A

LY117018 TFA	Estrogen Receptor/ERR	Cancer
LY117018 TFA, a Raloxifene analog, is a selective **estrogen receptor** modulator. LY117018 TFA exerts antiproliferative effects on breast cancer cell lines .

HY-114154

AL-438	Glucocorticoid Receptor	Inflammation/Immunology
AL-438 is a potent, selective and orally active glucocorticoid receptor modulator with K_is of 2.5, 1786, 53, 1440, >1000 nM for glucocorticoid receptor, progesterone receptor, mineralocorticoid receptor, androgen receptor, estrogen receptor, respectively. AL-438 shows antiinflammatory activity .

HY-126109

(±)-8-Prenylnaringenin	Estrogen Receptor/ERR Apoptosis	Metabolic Disease Endocrinology Cancer
(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen *Receptor/ERR) that inhibits ERα* and ERβ with IC₅₀s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research .

HY-135581

Raloxifene 6-glucuronide	Estrogen Receptor/ERR	Endocrinology
Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to **estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor** modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-135582

Raloxifene 4'-glucuronide	Estrogen Receptor/ERR	Endocrinology
Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to **estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor** modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-B2158S

Chlorotrianisene-d9	Estrogen Receptor/ERR COX	Cardiovascular Disease Endocrinology
Chlorotrianisene-d₉ is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood[1][2][3].

HY-16950A

(E/Z)-4-Hydroxytamoxifen 1 Publications Verification Afimoxifene	Estrogen Receptor/ERR Endogenous Metabolite	Cancer
(E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is an **estrogen receptor** modulator.

HY-W011100

Cyclofenil	Dengue virus Estrogen Receptor/ERR Flavivirus	Infection Endocrinology
Cyclofenil is a selective **estrogen receptor** modulator and an ovulation-inducing agent. Cyclofenil shows an inhibitory effect on dengue virus replication in Vero cells with an EC₅₀ of 1.62 μM. Cyclofenil has anti-dengue-virus activity .

HY-B0463

Clomiphene citrate 4 Publications Verification Clomifene citrate	Estrogen Receptor/ERR	Neurological Disease Endocrinology Cancer
Clomiphene citrate (Clomifene citrate) is an orally active **estrogen-receptor modulator**. Clomiphene citrate has anti-cancer actixity, induces perturbations during meiotic maturation and cytogenetic abnormalities and ameliorates in managing psychiatric and cognitive impairment .

HY-B0005A

Toremifene 5+ Cited Publications Z-Toremifene; NK 622 free base; FC-1157a free base	Estrogen Receptor/ERR	Infection Cancer
Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 µM and 2.6 µM, respectively .

HY-13757AS

Tamoxifen-d5 ICI 47699-d5; (Z)-Tamoxifen-d₅; trans-Tamoxifen-d₅	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen-d₅ is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity[1][2].

HY-A0037

Lasofoxifene CP-336156	Estrogen Receptor/ERR	Inflammation/Immunology Cancer
Lasofoxifene (CP-336156) is an orally active and selective **estrogen receptor** modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium	Estrogen Receptor/ERR	Endocrinology
Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].

HY-135582S1

Raloxifene 4'-glucuronide-d4 lithium	Estrogen Receptor/ERR	Endocrinology
Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. [1][2]. Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[3].

HY-127133

Methylpiperidino pyrazole MPP	Biochemical Assay Reagents
MPP is a highly selective estrogen receptor alpha (ERα) antagonist. MPP reduces the ratio of p-ERα/ERα . https://www.ncbi.nlm.nih.gov/pubmed/29799481 Labouesse MA, et al. Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice. Psychopharmacology (Berl). 2015 Aug;232(16):2981-94. https://www.ncbi.nlm.nih.gov/pubmed/25893642

HY-121149

Droloxifene 1 Publications Verification 3-Hydroxytamoxifen	Estrogen Receptor/ERR Apoptosis	Cancer
Droloxifene, a Tamoxifen derivative, is an orally active and selective **estrogen receptor** modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats .

HY-103454B

MPP hydrochloride 5+ Cited Publications	Estrogen Receptor/ERR Apoptosis	Endocrinology Cancer
MPP hydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP hydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP hydrochloride reverses the the positive effects of beta-estradiol. MPP hydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2371

27-Hydroxycholesterol 2 Publications Verification 27-OHC	Structural Classification Natural Products Classification of Application Fields Source classification Disease markers Nervous System Disorder Endogenous metabolite Disease Research Fields Cardiovascular System Disorder Cancer	Estrogen Receptor/ERR LXR Endogenous Metabolite
27-Hydroxycholesterol (27-OHC) is a selective **estrogen receptor** modulator and an agonist of the liver X receptor.

HY-13738A

Raloxifene hydrochloride Maximum Cited Publications 9 Publications Verification Keoxifene hydrochloride; LY156758; LY139481 hydrochloride	Alkaloids Piperidine Alkaloids Classification of Application Fields Source classification Rutaceae Phenols Polyphenols Plants Disease Research Fields Endocrinology Tetradium ruticarpum (A. Jussieu) T. G. Hartley Cancer	Estrogen Receptor/ERR Autophagy
Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active **estrogen receptor** modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .

HY-15731

Estetrol	Cardiovascular Disease Monophenols Classification of Application Fields Source classification Phenols Endogenous metabolite Disease Research Fields Steroids	Estrogen Receptor/ERR Endogenous Metabolite
Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear **estrogen receptor** modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast .

HY-16950A

(E/Z)-4-Hydroxytamoxifen 1 Publications Verification Afimoxifene	Structural Classification Alkaloids Monophenols Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields Cancer	Estrogen Receptor/ERR Endogenous Metabolite
(E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is an **estrogen receptor** modulator.

HY-13738AR

Raloxifene hydrochloride (Standard) Keoxifene (hydrochloride)(Standard); LY156758(Standard); LY139481 hydrochloride (Standard)	Structural Classification Alkaloids Classification of Application Fields Source classification Rutaceae Phenols Plants Disease Research Fields Endocrinology Tetradium ruticarpum (A. Jussieu) T. G. Hartley Cancer	Estrogen Receptor/ERR Autophagy
Raloxifene (hydrochloride) (Standard) is the analytical standard of Raloxifene (hydrochloride). This product is intended for research and analytical applications. Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation?selective and orally active **estrogen receptor** modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .

Cat. No.	Product Name	Chemical Structure

HY-15731S

Estetrol-d4
Estetrol-d₄ is the deuterium labeled Estetrol. Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast[1][2].

HY-13738S

Raloxifene-d4
Raloxifene-d₄ is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].

HY-13738S2

Raloxifene-d4 hydrochloride
Raloxifene-d₄ (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].

HY-13738S3

Raloxifene-d10
Raloxifene-d₁₀ is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].

HY-13738S4

Raloxifene-d10-1
Raloxifene-d₁₀-1 is the deuterium labeled Raloxifene[1]. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[2].

HY-B0723S

Ospemifene D4
Ospemifene-d₄ is a deuterium labeled Ospemifene. Ospemifene is a selective and orally active estrogen receptor modulator for the prevention of osteoporosis with IC50 values of 827 nM and 1633 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene has bone-sparing, antitumor, and cholesterol-lowering effects[1][2].

HY-B2158S

Chlorotrianisene-d9
Chlorotrianisene-d₉ is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood[1][2][3].

HY-13757AS

Tamoxifen-d5
Tamoxifen-d₅ is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity[1][2].

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium

Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].

HY-135582S1

Raloxifene 4'-glucuronide-d4 lithium

Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. [1][2]. Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[3].

HY-16950BS

(E)-4-Hydroxytamoxifen-d5
(E)-4-Hydroxytamoxifen-d5 ((E)-Afimoxifene-d5) is the deuterium labeled (E)-4-Hydroxytamoxifen. (E)-4-Hydroxytamoxifen ((E)-Afimoxifene), the less active isomer of (Z)-4-hydroxytamoxifen, is an **estrogen receptor** modulator.

HY-B0005AS

Toremifene-d6
Toremifene-d₆ is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].

HY-B0005S1

Toremifene-d6 hydrochloride
Toremifene-d6 (Z-Toremifene-d6) hydrochloride is deuterium labeled Toremifene. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 µM and 2.6 µM, respectively .

HY-B0005S

Toremifene-d6 citrate
Toremifene-d₆ (citrate) is the deuterium labeled Toremifene citrate. Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].

HY-13757AS1

Tamoxifen-d3

Tamoxifen-d₃ is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].

HY-A0031S

Bazedoxifene-d4

Bazedoxifene-d₄ is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].

HY-A0031S2

Bazedoxifene-d4 acetate

Bazedoxifene-d₄ (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks